O054 Biomarkers of Cellular Immune Response in Cervical Carcinoma

Ancuta, G.E.; Ancuţa, Codrina; Zugun‐Eloae, Florin; Carasevici, E

doi:10.1016/s0020-7292(12)60484-6

Cited by 9 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strongest discriminatory potential was attributed to densities of CD3+ in both intra-and peritumoral tissue; besides, according to a multiple regression model, CD3+ seems to be considered a potent prognostic factor for relapse (Ancuta, 2009). Nevertheless, no predictive biomarker is still validated for the use in clinical practice (Ancuta, 2009). …”

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

“…Moreover, the risk of progression to cervical carcinoma is higher for HPV types 16 and 18 than for other known types of HPV (Ancuta, 2009;Goncalves & Donadi, 2004;Scott, 2001). …”

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

“…The findings gained during the last years on persistent high risk HPV types in women developing cervical carcinoma have provided the basis for evaluation of the clinical utility of testing for cancer-associated HPV types (Ancuta, 2009;Goncalves & Donadi, 2004;Scott, 2001). …”

Section: Screening and Diagnosismentioning

confidence: 99%

“…Moreover, three different cell subsets including TCD3+, BCD20+ and CD45+ leucocytes have been extensively studied among women with or without recurrence of their cancer after the surgery (Ancuta, 2009). Higher densities infiltrates are thought to be associated with a better clinical outcome.…”

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

“…In addition, it seems that there is a relationship between different types of immune cells and survival: high density of cells is frequently observed in connection with free survival (Ancuta, 2009). The strongest discriminatory potential was attributed to densities of CD3+ in both intra-and peritumoral tissue; besides, according to a multiple regression model, CD3+ seems to be considered a potent prognostic factor for relapse (Ancuta, 2009). Nevertheless, no predictive biomarker is still validated for the use in clinical practice (Ancuta, 2009).…”

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

See 4 more Smart Citations

Predictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes"

Ancuta¹,

Ancuţa²,

Dumitru³

2012

Hysterectomy

View full text Add to dashboard Cite

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

“…Moreover, the risk of progression to cervical carcinoma is higher for HPV types 16 and 18 than for other known types of HPV (Ancuta, 2009;Goncalves & Donadi, 2004;Scott, 2001). …”

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

Section: Screening and Diagnosismentioning

confidence: 99%

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

Section: Immunological Aspects In Cervical Cancermentioning

confidence: 99%

See 3 more Smart Citations

Predictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes"

Ancuta¹,

Ancuţa²,

Dumitru³

2012

Hysterectomy

View full text Add to dashboard Cite

Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment

Lippens

Bockstal

Jaeghere

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated the potential of tumor-infiltrating immune cells (ICs) as predictive or prognostic biomarkers for cervical cancer patients. In total, 38 patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. This unique treatment schedule makes it possible to analyze IC markers in pretreatment and posttreatment tissue specimens and their changes during treatment. IC markers for T cells (CD3, CD4, CD8 and FoxP3), macrophages (CD68 and CD163) and B cells (CD20), as well as IL33 and PD-L1, were retrospectively analyzed via immunohistochemistry. Patients were grouped in the low score or high score group based on the amount of positive cells on immunohistochemistry. Correlations to pathological complete response (pCR), cause-specific survival (CSS) and metastasis development during follow-up were evaluated. In analysis of pretreatment biopsies, significantly more pCR was seen for patients with CD8 = CD3, CD8 ≥ CD4, positive IL33 tumor cell (TC) scores, IL33 IC < TC and PD-L1 TC ≥5%. Besides patients with high CD8 scores, also patients with CD8 ≥ CD4, CD163 ≥ CD68 or PD-L1 IC ≥5% had better CSS. In the analysis of posttreatment specimens, less pCR was observed for patients with high CD8 or CD163 scores. Patients with decreasing CD8 or CD163 scores between pretreatment and posttreatment samples showed more pCR, whereas those with increasing CD8 or decreasing IL33 IC scores showed a worse CSS. Meanwhile, patients with an increasing CD3 score or stable/increasing PD-L1 IC score showed more metastasis during follow-up. In this way, the intratumoral IC landscape is a promising tool for prediction of outcome and response to (chemo)radiotherapy.K.V. and H.D. contributed equally to this work Additional Supporting Information may be found in the online version of this article.

show abstract

Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas

et al. 2011

View full text Add to dashboard Cite

PurposeThe purpose of this study was to clarify the prognostic significance of lymphocyte infiltration in soft tissue sarcomas (STS). Prognostic markers in potentially curable STS should guide therapy after surgical resection. The immune status at the time of resection may be important, but the prognostic significance of tumor infiltrating lymphocytes is controversial as the immune system has conflicting roles during cancer development.Experimental DesignTissue microarrays from 249 patients with STS were constructed from duplicate cores of viable and representative neoplastic tumor areas. Immunohistochemistry was used to evaluate the CD3+, CD4+, CD8+, CD20+ and CD45+ lymphocytes in tumors.ResultsIn univariate analyses, increased numbers of CD4+ (P = 0.008) and CD20+ (P = 0.006) lymphocytes in tumor correlated significantly with an improved disease-specific survival (DSS) in patients with wide resection margins (n = 108). In patients with non-wide resection margins (n = 141) increased numbers of CD3+ (P = 0.028) lymphocytes in tumor correlated significantly with shorter DSS. In multivariate analyses, a high number of CD20+ lymphocytes (HR = 5.5, CI 95% = 1.6–18.6, P = 0.006) in the tumor was an independent positive prognostic factor for DSS in patients with wide resections margins.ConclusionsHigh density of CD20+ lymphocytes in STS with wide resection margins is an independent positive prognostic indicator for these patients. Further research is needed to define if CD20+ cells can modify tumors in a way that reduces disease progression and metastatic potential.

show abstract

O054 Biomarkers of Cellular Immune Response in Cervical Carcinoma

Cited by 9 publications

References 0 publications

Predictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes"

Predictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for Cervical Cancer in Relation to Clinical Outcomes"

Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment

Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas

Contact Info

Product

Resources

About